Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World July 10, 2012	Interview: EMA head Guido Rasi His five-year appointment comes during a period of dramatic change for the pharma industry, which is struggling with patent expirations for many of its biggest selling drugs and a paucity of new drugs coming through the pipeline to take their place.
Pharmaceutical Executive December 1, 2010 Zhu Shen	China 2020: Walled In No More Pharma sets the pace for China's ambitious new innovation agenda
Chemistry World October 11, 2007 Hepeng Jia	China's Drug Industry Set to Take Off Producing cheap drugs for the developing world could allow Chinese pharmaceutical firms to capture a bigger share of the international market, industry experts suggest.
The Motley Fool May 26, 2011 Brian Orelli	Congress Sets Bad Precedent With AVANIR What happened to free markets?
Chemistry World July 25, 2012	Pharma Industry May Suffer as India Looks to Generics India plans to provide free generic drugs to half its population.
Chemistry World December 20, 2013 Patrick Walter	Chinese police seize 222m pounds of fake drugs Counterfeit medicines and raw materials worth more than Yuan2.2 billion have been seized by Chinese authorities.
The Motley Fool July 11, 2007 Brian Lawler	Not All Pharmaceutical Markets Are the Same The case of China's former FDA leader highlights the issues facing the country's pharmaceutical industry. Investors, take note.
Chemistry World August 21, 2013 Phillip Broadwith	Two way traffic for Chinese drug licensing Chinese companies have trailed behind their Western counterparts in developing innovative new drugs. Very few of those inventions have been considered useful enough to be licensed by western companies. However, that appears to be changing.
The Motley Fool September 12, 2005 M.D. Mitchell	Big Problems for Big Pharma Creating new drugs is never easy, but the companies that excel in three key areas are the ones for investors to watch.
Pharmaceutical Executive July 3, 2007	Thought Leader: Connected Markets, Rob Dhoble It used to be that pharma companies had one marketing strategy for the US and other developed nations, a second strategy for emerging countries, and a third, mostly focused around access, for the developing world. But in a global environment, that doesn't work.
BusinessWeek September 4, 2008 Pete Engardio	Chinese Scientists Build Big Pharma Back Home In a reverse migration, U.S.-trained scientists are setting up biotech startups, contract-research companies, and university labs on the mainland.
Pharmaceutical Executive December 1, 2008 Patrick Clinton	Reason to Believe Here are a few things to be optimistic about in the pharmaceutical industry.
BusinessWeek April 18, 2005 Manjeet Kripalani	India: Bigger Pharma Tougher patent protection laws are spurring rapid growth in new drug research across India.
The Motley Fool December 27, 2007 Brian Orelli	Drugmaker Growth: The China Connection Just like other industries, the pharmaceutical industry has realized that China is a good place to find cheap labor. While reluctant to set up FDA-regulated manufacturing plants in China, other stages of drug development can be done there.
The Motley Fool July 30, 2010 Brian Orelli	A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs.
Chemistry World September 24, 2010 Andrew Turley	End of the road for Avandia? The European Medicines Agency has decided the troubled diabetes drug should be pulled from the market while the US Food and Drug Administration has said it will 'significantly restrict' its use.
Chemistry World March 17, 2014 Phillip Broadwith	UK to fast-track access to critical medicines Critically ill patients in the UK could receive new medicines before they are formally approved under a new scheme beginning in April.
The Motley Fool September 9, 2004 Charly Travers	The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated.
Pharmaceutical Executive February 1, 2009 Patrick Clinton	Working Together No one who cares about global health can be happy with a system that only "eventually" delivers drugs and vaccines for the planet's neediest people.
The Motley Fool April 12, 2011 Brian Orelli	Merck Joins the Low-Margin Party The American drugmaker announces that it is partnering with Sun Pharma to establish a joint venture to sell branded generics in emerging markets.
Chemistry World June 23, 2010 Sarah Houlton	A smaller future for big pharma? Cutting the amount spent on medicines may be an easy way for governments to help balance the books in the short term, but in the long run it will impact the ability to discover new medicines.
The Motley Fool January 24, 2006 Stephen D. Simpson	Reddy, Set, Go! After a tough stretch, leading Indian pharmaceutical company Dr. Reddy's may be ready to move again. This is still a turnaround story, though, so investors unable or unwilling to assume above-average risk should probably steer clear.
The Motley Fool October 18, 2010 Brian Orelli	Pfizer Flexes Its Generic Muscles The pharma giant moves farther into generic drugs.
Chemistry World September 11, 2012 Maria Burke	Orphan drugs set for 'tremendous growth' A new report by Thomson Reuters offers clear confirmation that developing drugs for rare, or orphan, diseases is economically attractive, despite the smaller patient pool.
Chemistry World July 15, 2008 Hepeng Jia	Testing Times for New Liver Drug AstraZeneca is set to start clinical trials of a liver cancer drug developed for Chinese patients.
Chemistry World July 11, 2012 Ling Wang	China Targets Patented Drugs with Law Change China has altered its licensing laws to allow domestic pharmaceutical companies to make cheap generic copies of patented drugs under certain circumstances.
The Motley Fool April 5, 2011 Frank Vinluan	GSK in Emerging Markets: Why Sales Staff There Are Key to Global Strategy GlaxoSmithKline's rivalry with top drug companies such as Pfizer goes beyond the products they sell. In some emerging markets, it now also extends to the staff they're fighting to keep.
Pharmaceutical Executive July 1, 2009	The Pharmerging Future A guide to grabbing growth in seven "pharmerging" markets.
Pharmaceutical Executive December 1, 2010 William Looney	In Through the Out Door The end of anther year is an appropriate time to highlight the march of time and the transitions that accompany it in Europe and in China.
Chemistry World November 18, 2010 Ned Stafford	New drug pricing rules in Germany The law was approved on 11 November and will take effect from 1 January as part of an effort to rein in exploding costs for Germany's massive public health insurance system.
BusinessWeek December 13, 2004 Bruce Einhorn	Go East, Big Pharma Drugmakers are expanding in China, but patents are still a worry.
The Motley Fool March 30, 2011 Sean Williams	China Clamps Down on Drug Manufacturers These drug manufacturers could be feeling a pinch from new Chinese price caps.
The Motley Fool May 13, 2008 Brian Orelli	Is Merck Keeping Its Enemies Close? The drugmaker strikes a deal with an Indian generic company.
Pharmaceutical Executive September 1, 2013 William Looney	High Noon For Hot Markets Fading growth, overstretched governments, and a global governance backlash against pharma business are turning up the heat on the performance of emerging country markets.
BusinessWeek April 15, 2010 Kanoko Matsuyama	Looking East, Big Pharma Cuts Prices Drugmakers are beginning to choose sales volume over high margins to tap the massive Asian market
Pharmaceutical Executive May 1, 2007	Thoughtleader: Thomas Nagle, Strategic Pricing Group This industry consultant believes the U.S. government will soon follow Europe's lead in taking a greater hand in price negotiations, and pharma will need to be able to communicate the value that products offer. Here he discusses how pharma can meet that challenge.
Chemistry World May 27, 2015 Phillip Broadwith	Label laundry It's been an interesting month in the world of off-label pharmaceuticals.
Chemistry World September 17, 2010 Andrew Turley	Free trade could throttle generics from India International agreements on intellectual property threaten the flow of generic HIV drugs from India to developing countries, according to a new report.
Pharmaceutical Executive September 1, 2006 Patrick Clinton	From the Editor: Undecided People are buying drugs, because companies are selling drugs. Interfere with the selling process, and people won't buy as many drugs.
Pharmaceutical Executive October 1, 2011 Jill Wechsler	At the Helm of Industry As the lead FDA official overseeing the testing and approval of new drugs and biotech therapies for some 20 years, Dr. Janet Woodcock has built a robust and modern drug regulatory system.
The Motley Fool January 29, 2010 Brian Orelli	How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years.
Chemistry World January 6, 2015 Sarah Houlton	Riding new waves Global annual spending on medicines is set to top $1 trillion for the first time in 2014, having ended 2013 just shy of that figure at $989 billion.
Chemistry World July 13, 2007 Hepeng Jia	Chinese Legislation to Increase Drug Safety A long-awaited amendment to China's drug registration system is expected to discipline the country's medical sector and boost the pharmaceutical industry.
Pharmaceutical Executive October 1, 2006 Ray Hill	China: Big Rewards. Bigger Risks? The world's fastest growing pharmaceutical market may one day be the largest. Breaking in could be industry's greatest challenge.
The Motley Fool July 21, 2004 Brian Gorman	Novartis Shows the Way It may be a model for other pharmaceutical outfits looking to improve productivity.
The Motley Fool November 30, 2010 Brian Orelli	A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist.
The Motley Fool May 21, 2010 Brian Orelli	And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.
Chemistry World September 6, 2013 Dinsa Sachan	Another drug suspension overturned in India An Indian high court has quashed the suspension of a popular antidepressant. This comes shortly after the suspension of the diabetes drug pioglitazone was overturned.
Pharmaceutical Executive January 1, 2011	The Steep, Slow Climb A survey of leading experts reveals 2011's sobering reality and the trends that smart drugmakers will follow into the next decade.
Pharmaceutical Executive August 1, 2011 Ben Comer	Is the 'Emerging Market' a Dated Concept? When it comes to the emerging markets, executing a few key elements of success are more important than ever.